SG11202009783WA - Compositions and methods for gene editing - Google Patents

Compositions and methods for gene editing

Info

Publication number
SG11202009783WA
SG11202009783WA SG11202009783WA SG11202009783WA SG11202009783WA SG 11202009783W A SG11202009783W A SG 11202009783WA SG 11202009783W A SG11202009783W A SG 11202009783WA SG 11202009783W A SG11202009783W A SG 11202009783WA SG 11202009783W A SG11202009783W A SG 11202009783WA
Authority
SG
Singapore
Prior art keywords
compositions
methods
gene editing
editing
gene
Prior art date
Application number
SG11202009783WA
Inventor
Jin CHEN
Luke Gilbert
James Nunez
Jonathan Weissman
Original Assignee
Univ California
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ California filed Critical Univ California
Publication of SG11202009783WA publication Critical patent/SG11202009783WA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C12N15/90—Stable introduction of foreign DNA into chromosome
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/1003—Transferases (2.) transferring one-carbon groups (2.1)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/1003—Transferases (2.) transferring one-carbon groups (2.1)
    • C12N9/1007—Methyltransferases (general) (2.1.1.)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
    • C12N9/18—Carboxylic ester hydrolases (3.1.1)
    • C12N9/20—Triglyceride splitting, e.g. by means of lipase
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
    • C12N9/22—Ribonucleases RNAses, DNAses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/09—Fusion polypeptide containing a localisation/targetting motif containing a nuclear localisation signal
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/20—Type of nucleic acid involving clustered regularly interspaced short palindromic repeats [CRISPRs]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/22—Vectors comprising a coding region that has been codon optimised for expression in a respective host
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y201/00—Transferases transferring one-carbon groups (2.1)
    • C12Y201/01—Methyltransferases (2.1.1)
    • C12Y201/01072—Site-specific DNA-methyltransferase (adenine-specific) (2.1.1.72)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y301/00—Hydrolases acting on ester bonds (3.1)
SG11202009783WA 2018-04-19 2019-04-19 Compositions and methods for gene editing SG11202009783WA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862660023P 2018-04-19 2018-04-19
PCT/US2019/028377 WO2019204766A1 (en) 2018-04-19 2019-04-19 Compositions and methods for gene editing

Publications (1)

Publication Number Publication Date
SG11202009783WA true SG11202009783WA (en) 2020-11-27

Family

ID=68238979

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11202009783WA SG11202009783WA (en) 2018-04-19 2019-04-19 Compositions and methods for gene editing

Country Status (13)

Country Link
US (3) US11434491B2 (en)
EP (1) EP3781705A4 (en)
JP (1) JP2021521788A (en)
KR (1) KR20210003819A (en)
CN (2) CN112334577B (en)
AU (1) AU2019255789A1 (en)
BR (1) BR112020021229A2 (en)
CA (1) CA3096713A1 (en)
GB (1) GB2587970B (en)
IL (1) IL277837A (en)
MX (1) MX2020010974A (en)
SG (1) SG11202009783WA (en)
WO (1) WO2019204766A1 (en)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112020021229A2 (en) 2018-04-19 2021-02-02 The Regents Of The University Of California compositions and methods for editing genes
GB2612212A (en) * 2020-06-02 2023-04-26 Univ California Compositions and methods for gene editing
WO2021247570A2 (en) * 2020-06-02 2021-12-09 The Regents Of The University Ofcalifornia Compositions and methods for gene editing
JP2024501383A (en) * 2020-12-22 2024-01-11 クロマ・メディシン，インコーポレーテッド Compositions and methods for epigenetic editing
CN117413062A (en) * 2021-02-01 2024-01-16 爱普思伦生物公司 Gene silencing
WO2023093862A1 (en) * 2021-11-26 2023-06-01 Epigenic Therapeutics Inc. Method of modulating pcsk9 and uses thereof
CN113999873B (en) * 2021-12-31 2022-05-20 北京市疾病预防控制中心 Construction method and application of genetically modified non-human animal
WO2023173110A1 (en) * 2022-03-11 2023-09-14 Epicrispr Biotechnologies, Inc. Compositions, systems, and methods for treating familial hypercholesterolemia by targeting pcsk9
WO2023215711A1 (en) * 2022-05-01 2023-11-09 Chroma Medicine, Inc. Compositions and methods for epigenetic regulation of pcsk9 expression
WO2023250490A1 (en) * 2022-06-23 2023-12-28 Chroma Medicine, Inc. Compositions and methods for epigenetic regulation of trac expression
WO2023250148A1 (en) * 2022-06-23 2023-12-28 Chroma Medicine, Inc. Compositions and methods for epigenetic editing
WO2023250509A1 (en) * 2022-06-23 2023-12-28 Chroma Medicine, Inc. Compositions and methods for epigenetic regulation of b2m expression
WO2023250512A1 (en) * 2022-06-23 2023-12-28 Chroma Medicine, Inc. Compositions and methods for epigenetic regulation of ciita expression
WO2023250511A2 (en) * 2022-06-24 2023-12-28 Tune Therapeutics, Inc. Compositions, systems, and methods for reducing low-density lipoprotein through targeted gene repression
CN117143257B (en) * 2023-10-31 2024-02-09 深圳市帝迈生物技术有限公司 TRIM28-KRAB-ZNF10 binary complex, preparation method and kit for screening prostate cancer

Family Cites Families (82)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1276859B1 (en) 2000-04-28 2007-02-07 Sangamo Biosciences Inc. Targeted modification of chromatin structure
US6919204B2 (en) 2000-09-29 2005-07-19 Sangamo Biosciences, Inc. Modulation of gene expression using localization domains
WO2003072788A1 (en) 2002-02-21 2003-09-04 The Wistar Institute Of Anatomy And Biology Methods and compositions for reversibly controlling expression of target genes in cells
US20070192880A1 (en) 2003-10-03 2007-08-16 University Of Rochester Horming response element binding transregulators
GB0526449D0 (en) 2005-12-23 2006-02-08 Medical Res Council Polypeptide targeting
KR100756055B1 (en) 2006-01-27 2007-09-07 연세대학교 산학협력단 Recombinant Adenoviruses Capable of Regulating Angiogenesis
GB0607063D0 (en) 2006-04-07 2006-05-17 Cellcentric Ltd Compositions and methods for epigenetic modification of nucleic acid sequences in vivo
WO2010108126A2 (en) 2009-03-19 2010-09-23 Fate Therapeutics, Inc. Reprogramming compositions and methods of using the same
US10323236B2 (en) 2011-07-22 2019-06-18 President And Fellows Of Harvard College Evaluation and improvement of nuclease cleavage specificity
WO2013130807A1 (en) 2012-02-28 2013-09-06 Sigma-Aldrich Co. Llc Targeted histone acetylation
WO2013141680A1 (en) 2012-03-20 2013-09-26 Vilnius University RNA-DIRECTED DNA CLEAVAGE BY THE Cas9-crRNA COMPLEX
PL2800811T3 (en) 2012-05-25 2017-11-30 Emmanuelle Charpentier Methods and compositions for rna-directed target dna modification and for rna-directed modulation of transcription
PT2912175T (en) 2012-10-23 2018-11-05 Toolgen Inc Composition for cleaving a target dna comprising a guide rna specific for the target dna and cas protein-encoding nucleic acid or cas protein, and use thereof
PT3363902T (en) 2012-12-06 2019-12-19 Sigma Aldrich Co Llc Crispr-based genome modification and regulation
JP6552965B2 (en) 2012-12-12 2019-07-31 ザ・ブロード・インスティテュート・インコーポレイテッド Engineering and optimization of improved systems, methods and enzyme compositions for sequence manipulation
KR20150105635A (en) 2012-12-12 2015-09-17 더 브로드 인스티튜트, 인코퍼레이티드 Crispr-cas component systems, methods and compositions for sequence manipulation
US8697359B1 (en) 2012-12-12 2014-04-15 The Broad Institute, Inc. CRISPR-Cas systems and methods for altering expression of gene products
PT2771468E (en) 2012-12-12 2015-06-02 Harvard College Engineering of systems, methods and optimized guide compositions for sequence manipulation
US20140310830A1 (en) 2012-12-12 2014-10-16 Feng Zhang CRISPR-Cas Nickase Systems, Methods And Compositions For Sequence Manipulation in Eukaryotes
US8993233B2 (en) 2012-12-12 2015-03-31 The Broad Institute Inc. Engineering and optimization of systems, methods and compositions for sequence manipulation with functional domains
MX2015007743A (en) 2012-12-17 2015-12-07 Harvard College Rna-guided human genome engineering.
US10760064B2 (en) 2013-03-15 2020-09-01 The General Hospital Corporation RNA-guided targeting of genetic and epigenomic regulatory proteins to specific genomic loci
CN112301024A (en) 2013-03-15 2021-02-02 通用医疗公司 Increasing specificity of RNA-guided genome editing using RNA-guided FokI nuclease (RFN)
US20140356956A1 (en) 2013-06-04 2014-12-04 President And Fellows Of Harvard College RNA-Guided Transcriptional Regulation
WO2014197748A2 (en) 2013-06-05 2014-12-11 Duke University Rna-guided gene editing and gene regulation
EP3825406A1 (en) * 2013-06-17 2021-05-26 The Broad Institute Inc. Delivery and use of the crispr-cas systems, vectors and compositions for hepatic targeting and therapy
EP3011035B1 (en) * 2013-06-17 2020-05-13 The Broad Institute, Inc. Assay for quantitative evaluation of target site cleavage by one or more crispr-cas guide sequences
CN110819658B (en) 2013-07-10 2024-03-22 哈佛大学校长及研究员协会 Orthogonal Cas9 proteins for RNA-guided gene regulation and editing
US9526784B2 (en) 2013-09-06 2016-12-27 President And Fellows Of Harvard College Delivery system for functional nucleases
CN106536729A (en) * 2013-12-12 2017-03-22 布罗德研究所有限公司 Delivery, use and therapeutic applications of the crispr-cas systems and compositions for targeting disorders and diseases using particle delivery components
US20150191744A1 (en) 2013-12-17 2015-07-09 University Of Massachusetts Cas9 effector-mediated regulation of transcription, differentiation and gene editing/labeling
CA2942915A1 (en) 2014-03-20 2015-09-24 Universite Laval Crispr-based methods and products for increasing frataxin levels and uses thereof
WO2016011080A2 (en) 2014-07-14 2016-01-21 The Regents Of The University Of California Crispr/cas transcriptional modulation
EP3169702A4 (en) 2014-07-14 2018-04-18 The Regents of The University of California A protein tagging system for in vivo single molecule imaging and control of gene transcription
US20170233762A1 (en) 2014-09-29 2017-08-17 The Regents Of The University Of California Scaffold rnas
WO2016057061A2 (en) 2014-10-10 2016-04-14 Massachusetts Eye And Ear Infirmary Efficient delivery of therapeutic molecules in vitro and in vivo
GB201418965D0 (en) * 2014-10-24 2014-12-10 Ospedale San Raffaele And Fond Telethon
MX2017009506A (en) 2015-01-28 2017-11-02 Pioneer Hi Bred Int Crispr hybrid dna/rna polynucleotides and methods of use.
US10676726B2 (en) 2015-02-09 2020-06-09 Duke University Compositions and methods for epigenome editing
US11674144B2 (en) * 2015-04-16 2023-06-13 California Institute Of Technology Fractional regulation of transcription
US10676735B2 (en) 2015-07-22 2020-06-09 Duke University High-throughput screening of regulatory element function with epigenome editing technologies
CN108243607A (en) 2015-09-09 2018-07-03 西雅图儿童医院（Dba西雅图儿童研究所） For the genetic engineering of the macrophage of immunotherapy
EP3147363B1 (en) 2015-09-26 2019-10-16 B.R.A.I.N. Ag Activation of taste receptor genes in mammalian cells using crispr-cas-9
EP3382018B1 (en) 2015-11-25 2022-03-30 National University Corporation Gunma University Dna methylation editing kit and dna methylation editing method
US11208652B2 (en) 2016-02-04 2021-12-28 President And Fellows Of Harvard College Mitochondrial genome editing and regulation
US20190127713A1 (en) 2016-04-13 2019-05-02 Duke University Crispr/cas9-based repressors for silencing gene targets in vivo and methods of use
US20190100732A1 (en) 2016-06-02 2019-04-04 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. Assay for the removal of methyl-cytosine residues from dna
US11471462B2 (en) 2016-06-27 2022-10-18 The Broad Institute, Inc. Compositions and methods for detecting and treating diabetes
CN109790527A (en) 2016-07-26 2019-05-21 通用医疗公司 The variant of the CRISPR1 (Cpf1) of general Bordetella and Francisella
EP3497221A4 (en) 2016-08-10 2020-02-05 Duke University Compositions, systems and methods for programming immune cell function through targeted gene regulation
CN106526789B (en) 2016-08-26 2019-03-22 玉晶光电(厦门)有限公司 Optical imaging lens
CA3036695A1 (en) 2016-09-13 2018-03-22 The Jackson Laboratory Targeted enhanced dna demethylation
WO2018085842A1 (en) 2016-11-07 2018-05-11 University Of Massachusetts Therapeutic targets for facioscapulohumeral muscular dystrophy
US20190300868A1 (en) 2016-12-15 2019-10-03 The Regents Of The University Of California Compositions and methods for crispr-based screening
EP3565548A4 (en) 2017-01-04 2020-10-14 The Board of Trustees of the Leland Stanford Junior University Target genes in myc-driven neoplasia
SG11201905508VA (en) 2017-01-23 2019-08-27 Regeneron Pharma Hsd17b13 variants and uses thereof
EP3579858A4 (en) 2017-02-07 2020-12-23 The Regents of The University of California Gene therapy for haploinsufficiency
WO2018148667A1 (en) 2017-02-10 2018-08-16 Memorial Sloan-Kettering Cancer Center Reprogramming cell aging
EP3655533A1 (en) 2017-02-24 2020-05-27 Georg-August-Universität Göttingen Stiftung Öffentlichen Rechts, Universitätsmedizin Method for re-expression of different hypermethylated genes involved in fibrosis, like hypermethylated rasal,1 and use thereof in treatment of fibrosis as well as kit of parts for re-expression of hypermethylated genes including rasal1 in a subject
BR112019021719A2 (en) 2017-04-21 2020-06-16 The General Hospital Corporation CPF1 VARIANT (CAS12A) WITH CHANGED PAM SPECIFICITY
CN110799205A (en) 2017-04-21 2020-02-14 通用医疗公司 Inducible, regulatable and multiplexed human gene regulation using CRISPR-Cpf1
IL309801A (en) 2017-07-11 2024-02-01 Sigma Aldrich Co Llc Using nucleosome interacting protein domains to enhance targeted genome modification
US11072782B2 (en) 2017-07-24 2021-07-27 Albert-Ludwigs-Universitaet Freiburg Construct for epigenetic modification and its use in the silencing of genes
US20190024072A1 (en) 2017-07-24 2019-01-24 Albert-Ludwigs-Universitaet Freiburg Construct for epigenetic modification and its use in the silencing of genes
MA50579A (en) 2017-11-09 2020-09-16 Crispr Therapeutics Ag AUTO-INACTIVATION (INS) CRISPR / CAS OR CRISPR / CPF1 SYSTEMS AND THEIR USES
MX2020005561A (en) 2017-12-01 2020-10-12 Encoded Therapeutics Inc Engineered dna binding proteins.
US11807850B2 (en) 2017-12-06 2023-11-07 Klogenix Llc Compositions and methods for modulating gene expression
WO2019117662A2 (en) * 2017-12-14 2019-06-20 단국대학교 산학협력단 Crispr system specific to tert promoter mutation and use thereof
KR102117016B1 (en) * 2017-12-14 2020-05-29 단국대학교 산학협력단 Method of CRISPR system enhancement and use thereof
JP2021507924A (en) 2017-12-22 2021-02-25 ディストリビューテッド バイオ， インコーポレイテッド Major histocompatibility complex (MHC) composition and how to use it
JP2021513866A (en) 2018-02-27 2021-06-03 ザ・ユニヴァーシティ・オヴ・ノース・キャロライナ・アト・チャペル・ヒル Methods and Compositions for Treating Angelman Syndrome
CA3096708A1 (en) 2018-04-18 2019-10-24 Yale University Compositions and methods for multiplexed tumor vaccination with endogenous gene activation
BR112020021229A2 (en) 2018-04-19 2021-02-02 The Regents Of The University Of California compositions and methods for editing genes
JP2021523696A (en) 2018-04-23 2021-09-09 デューク ユニバーシティ Downward regulation of SNCA expression by targeted editing of DNA methylation
WO2019210279A1 (en) 2018-04-27 2019-10-31 The Regents Of The University Of California De novo formation of the biliary system by hepatocyte transdifferentiation
EP3810273A4 (en) 2018-05-15 2022-03-16 The Children's Hospital of Philadelphia Crispr interference based htt allelic suppression and treatment of huntington disease
EP3802802A4 (en) 2018-05-30 2023-04-19 Tune Therapeutics, Inc. Cell therapy
WO2020006409A1 (en) 2018-06-28 2020-01-02 Trustees Of Boston University Systems and methods for control of gene expression
JP2021534205A (en) 2018-08-24 2021-12-09 ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティー Systems and methods for the spatial composition of polynucleotides
US20220033464A1 (en) 2018-08-24 2022-02-03 La Jolla Institute For Immunology Methods and compositons for modulations of immune response
CN113195002A (en) 2018-10-02 2021-07-30 桑格摩生物治疗股份有限公司 Engineered genetic modulators
CA3119618A1 (en) 2018-11-16 2020-05-22 Astellas Pharma Inc. Method for treating muscular dystrophy by targeting utrophin gene

Also Published As

Publication number Publication date
JP2021521788A (en) 2021-08-30
BR112020021229A2 (en) 2021-02-02
MX2020010974A (en) 2021-01-20
US20230103909A1 (en) 2023-04-06
US11434491B2 (en) 2022-09-06
WO2019204766A1 (en) 2019-10-24
CA3096713A1 (en) 2019-10-24
CN117534769A (en) 2024-02-09
IL277837A (en) 2020-11-30
CN112334577A (en) 2021-02-05
GB2587970B (en) 2023-02-08
CN112334577B (en) 2023-10-17
US20210139918A1 (en) 2021-05-13
EP3781705A4 (en) 2022-01-26
AU2019255789A1 (en) 2020-10-22
GB202017929D0 (en) 2020-12-30
KR20210003819A (en) 2021-01-12
EP3781705A1 (en) 2021-02-24
US20230124253A1 (en) 2023-04-20
GB2587970A (en) 2021-04-14

Similar Documents

Publication Publication Date Title
GB2587970B (en) Compositions and methods for gene editing
IL282191A (en) Methods and compositions for editing rnas
IL273817A (en) Compositions and methods for editing rna
IL277079A (en) Cartyrin compositions and methods for use
HK1256817A1 (en) Compositions and methods for genome editing
IL287248A (en) Methods and compositions for editing rnas
EP3362104A4 (en) Methods and compositions utilizing cpf1 for rna-guided gene editing
EP3850088A4 (en) Compositions and methods for improving base editing
IL271232A (en) Compositions and methods for genome editing
IL268788A (en) Compositions and methods for enhanced gene expression
IL281109A (en) Compositions and methods for enhancing triplex and nuclease-based gene editing
SG11202103571XA (en) Compositions and methods for immunotherapy
IL273999A (en) Compositions and methods for gene editing for hemophilia a
IL281108A (en) Compositions and methods for enhancing donor oligonucleotide-based gene editing
WO2017107898A9 (en) Compositions and methods for gene editing
EP3781677A4 (en) Compositions and methods for improved gene editing
EP3781683A4 (en) Methods and compositions for genome editing
IL290840A (en) Compositions and methods for cd123 modification
GB201907733D0 (en) Methods and compositions for multiplex gene editing
EP3796894A4 (en) Methods and compositions for genome editing
IL288313A (en) Compositions and methods for selective gene regulation
IL288024A (en) Methods and compositions for preventing type
IL283644A (en) Compositions and methods for immunotherapy
IL282369A (en) Compositions and methods for delivering transgenes
EP3723733A4 (en) Methods and compositions for treating cancer using exosomes-associated gene editing